Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent dosing of alendronate.

E C Tsun1, A M Heck

  • 1School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis, IN, USA.

The Annals of Pharmacotherapy
|November 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of computerized documentation system use in drug information centers.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Potential interactions between alternative therapies and warfarin.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Orlistat, a new lipase inhibitor for the management of obesity.

Pharmacotherapy·2000
Same author

Lamotrigine for the treatment of bipolar disorder.

The Annals of pharmacotherapy·2000
Same author

Amphetamines to counteract opioid-induced sedation.

The Annals of pharmacotherapy·2000

Intermittent alendronate dosing may improve patient compliance and reduce adverse events, but more research is needed. The effectiveness of this dosing schedule for postmenopausal osteoporosis is still undetermined.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Osteoporosis Research

Background:

  • Alendronate is a bisphosphonate commonly used for osteoporosis.
  • Traditional daily dosing can be associated with compliance issues and gastrointestinal side effects.

Purpose of the Study:

  • To review existing data on the use of intermittent dosing of alendronate.
  • To assess the potential benefits of intermittent dosing for patient compliance and adverse event profiles.

Main Methods:

  • A comprehensive literature search was performed.
  • Databases searched included MEDLINE and EMBASE.
  • The search focused on studies evaluating intermittent alendronate dosing.

Main Results:

Related Experiment Videos

  • A limited number of clinical studies have investigated intermittent alendronate dosing.
  • These studies aimed to improve patient adherence and mitigate adverse events.

    • Conclusions:

    • Further controlled clinical trials and postmarketing data are required.
    • The therapeutic efficacy and tolerability of intermittent alendronate dosing need to be confirmed.
    • The definitive role of intermittent dosing in managing postmenopausal osteoporosis remains uncertain.